Loading
Every dated change on the records linked to Relapsed or refractory chronic lymphocytic leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)
PFS 11.
A milestone in how this cancer is treated.
Venetoclax plus rituximab greatly lengthened progression-free survival compared with bendamustine-rituximab, with high rates of undetectable minimal residual disease; approved in June 2018.
A milestone in how this cancer is treated.
Relapsed CLL (RESONATE); del(17p) CLL
Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)
PFS HR 0.
A milestone in how this cancer is treated.